论文部分内容阅读
分别用含ＶＰ－１６的ＣＥＰ和ＥＰ方案及含ＶＭ－２６的ＶＭ－２６＋ＤＤＰ和ＶＭ－２６＋Ｃａｒｂｏｐｌａｔｉｎ方案合并放射治疗小细胞肺癌患者共７４例，以比较二者的近、远期疗效和毒副作用。结果示：ＶＰ－１６组有效率为９０．７％，ＶＭ－２６组为９３．５５％；ＶＰ－１６组的两年存活率为４４．１９％，ＶＭ－２６组为４８．３９％；ＶＰ－１６组的脑转移率为１４％，ＶＭ－２６组为１２．９％；ＶＰ－１６组的３～４级血液毒性发生率为２７．９１％，ＶＭ－２６组为５８．０６％。提示ＶＰ－１６与铂类联合的ＣＥＰ，ＥＰ方案和ＶＭ－２６＋ＤＤＰ，ＶＭ－２６＋Ｃａｒｂｏｐｌａｔｉｎ方案均可视为治疗小细胞肺癌的有效方案。ＶＭ－２６对预防小细胞肺癌的脑转移未见显著优势
A total of 74 patients with small cell lung cancer were treated with CEP and EP regimens containing VP-16 and VM-26+DDP and VM-26+Carboplatin regimens with VM-26, respectively, to compare the near, long-term efficacy, and side effects of both. The results showed that the effective rate was 90.7% in the VP-16 group and 93.55% in the VM-26 group; the two-year survival rate was 44.19% in the VP-16 group and 48.39% in the VM-26 group; The brain metastasis rate was 14% in the VP-16 group and 12.9% in the VM-26 group; the hematologic toxicity rate in the 3-4 group was 3.9 in the VP-16 group and 58.06% in the VM-26 group. . The combination of VP-16 and platinum-based CEP, EP regimen, VM-26+DDP, and VM-26+Carboplatin regimen can be regarded as an effective treatment for small cell lung cancer. VM-26 has no significant advantage in preventing brain metastasis of small cell lung cancer